Anti-vaping advocates often claim that e-cig vapor is just as toxic with carcinogens as the smoke from combustible cigarettes, but scientists from BioReliance in Rockville, MD, strongly disagree. According to a new vaping study released by the Maryland group, cigarettes contain some 6,000 additional chemicals that are not found in the e-liquids of electronic cigarettes. And of these thousands of noxious chemicals, some 150 are proven to be carcinogenic or cancer-causing.
An overview of the BioReliance e-cig study
The BioReliance team began their study by evaluating the e-cig vapor from a Vype ePen containing vape juice with a nicotine concentration of 18mg/ml. The device was also documented to have rechargeable battery and replaceable cartridge systems.
They measured the vapor for levels of the 150 genotoxic and nongenotoxic cancer-causing agents found in conventional cigarettes. However, the BioRelianceteam were especially interested in the nongenotoxic varieties because they are well-documented to lead to increased tumor production in cancer patients.
Meanwhile, the researchers also followed the same protocols by measuring the smoke produced from a King-sized cigarette made with American-grown tobacco leaves and containing 9.4 mg of tar, which adheres to International Organisation of Standardisation (ISO) regulations. What the scientists discovered is that the e-cig vapor from the Vype ePen was virtually 100% free of any measurable carcinogens, unlike the conventional tobacco cigarettes.
“Approximately 150 mg of TPM or ACM were collected on 44 mm Cambridge filter pads (Whatman, Maidstone, UK). The same number of puffs was used to generate enough TPM/ACM from each product for each pad (4 sticks of 3R4F (10 puffs/stick) and 40 puffs from the e-cigarette). Pads were weighed before and after TPM/ACM collection. Dimethylsulphoxide (DMSO) was used to elute the TPM or ACM from the pads to a stock concentration of 24 mg/mL Additional pads were prepared in parallel for determination of water and nicotine content in the TPM/ACM. A single batch each of 3R4F TPM and e-cigarette ACM was created for all experiments, by pooling the extracts from a number of pads. The extracts were stored in single-use volumes at −80°C. The samples were shipped on dry ice to the testing facility and stored at ≤–60°C until required.”
The results of the BioReliance research are published in the report entitled Comparative tumor promotion assessment of e-cigarette and cigarettes using the in vitro Bhas 42 cell transformation assay is readily available for review via Environmental and Molecular Mutagenesis. According to the co-authors, this is the first vaping study in history to focus on the possible associations between vaping and tumor production in cancer victims. They also acknowledge that the research was funded by Big Tobacco company British American Tobacco. But BioReliance believes this is a non-issue, stating that the results clearly show that e-cigs “have reduced tumor promoter activity compared to conventional cigarettes”